Abstract

BackgroundNSC-741909 is a novel anticancer agent that can effectively suppress the growth of several cell lines derived from lung, colon, breast, ovarian, and kidney cancers. We recently showed that NSC-741909-induced antitumor activity is associated with sustained Jun N-terminal kinase (JNK) activation, resulting from suppression of JNK dephosphorylation associated with decreased protein levels of MAPK phosphatase-1. However, the mechanisms of NSC-741909-induced antitumor activity remain unclear. Because JNK is frequently activated by oxidative stress in cells, we hypothesized that reactive oxygen species (ROS) may be involved in the suppression of JNK dephosphorylation and the cytotoxicity of NSC-741909.MethodsThe generation of ROS was measured by using the cell-permeable nonfluorescent compound H2DCF-DA and flow cytometry analysis. Cell viability was determined by sulforhodamine B assay. Western blot analysis, immunofluorescent staining and flow cytometry assays were used to determine apoptosis and molecular changes induced by NSC-741909.ResultsTreatment with NSC-741909 induced robust ROS generation and marked MAPK phosphatase-1 and -7 clustering in NSC-741909-sensitive, but not resistant cell lines, in a dose- and time-dependent manner. The generation of ROS was detectable as early as 30 min and ROS levels were as high as 6- to 8-fold above basal levels after treatment. Moreover, the NSC-741909-induced ROS generation could be blocked by pretreatment with antioxidants, such as nordihydroguaiaretic acid, aesculetin, baicalein, and caffeic acid, which in turn, inhibited the NSC-741909-induced JNK activation and apoptosis.ConclusionOur results demonstrate that the increased ROS production was associated with NSC-741909-induced antitumor activity and that ROS generation and subsequent JNK activation is one of the primary mechanisms of NSC-741909-mediated antitumor cell activity.

Highlights

  • NSC-741909 is a novel anticancer agent that can effectively suppress the growth of several cell lines derived from lung, colon, breast, ovarian, and kidney cancers

  • Our results demonstrate that the increased reactive oxygen species (ROS) production was associated with NSC-741909-induced antitumor activity and that ROS generation and subsequent Jun N-terminal kinase (JNK) activation is one of the primary mechanisms of NSC741909-mediated antitumor cell activity

  • Using a reverse-phase protein microarray assay, we determined molecular changes in 77 protein biomarkers in an oncrasin-sensitive lung cancer cell line after treatment with NSC-741909 [2]. These results showed that treatment with NSC-741909 induced persistent activation of mitogen-activated protein kinases (MAPKs), including p38 MAPK, Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK), and that persistent JNK activation is associated with apoptosis induction by this compound [2]

Read more

Summary

Introduction

NSC-741909 is a novel anticancer agent that can effectively suppress the growth of several cell lines derived from lung, colon, breast, ovarian, and kidney cancers. We recently showed that NSC-741909-induced antitumor activity is associated with sustained Jun N-terminal kinase (JNK) activation, resulting from suppression of JNK dephosphorylation associated with decreased protein levels of MAPK phosphatase-1. Accumulating evidence has demonstrated that, like other protein tyrosine phosphatases, the conserved catalytic cysteine residue in the active motif of MKPs is highly susceptible to reversible oxidation by local reactive oxygen species (ROS) such as hydrogen peroxide (H2O2) [5,6], which leads to inactivation of MKPs and activation of MAPKs [7,8,9]. ROS-induced oxidative stress and cell death play important roles in the efficacy of many antineoplastic agents [13,14]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call